138 related articles for article (PubMed ID: 6221642)
41. Effect of des-amino-D-arginine vasopressin (DDAVP) on plasma levels of platelet and endothelial cell release products.
D'Angelo A; Capitanio A; Smith JB; Valsecchi C; Mannucci PM
Thromb Haemost; 1983 Feb; 49(1):64-5. PubMed ID: 6687766
[No Abstract] [Full Text] [Related]
42. [Changes in the level of prostanoids in blood during whole-body irradiation of rats].
Navrátil L; Pospísil J; Blehová Z
Sb Lek; 1988 Oct; 90(10):302-9. PubMed ID: 3060977
[No Abstract] [Full Text] [Related]
43. The role of thromboxane in primate endotoxin shock.
Casey LC; Fletcher JR; Zmudka MI; Ramwell PW
J Surg Res; 1985 Aug; 39(2):140-9. PubMed ID: 3839548
[TBL] [Abstract][Full Text] [Related]
44. Effect of DP-1904, a new thromboxane A2 synthetase inhibitor, on guinea pig experimental asthma.
Takami M; Takata Y; Matsumoto K; Ono S; Tsukada W
Ann N Y Acad Sci; 1991; 629():407-9. PubMed ID: 1952565
[No Abstract] [Full Text] [Related]
45. Elevated thromboxane levels in the rat during endotoxic shock: protective effects of imidazole, 13-azaprostanoic acid, or essential fatty acid deficiency.
Cook JA; Wise WC; Halushka PV
J Clin Invest; 1980 Jan; 65(1):227-30. PubMed ID: 7350199
[TBL] [Abstract][Full Text] [Related]
46. The influence of selective thromboxane synthetase inhibition with a novel imidazole derivative, UK-38,485, on prostanoid formation in man.
Fischer S; Struppler M; Böhlig B; Bernutz C; Wober W; Weber PC
Circulation; 1983 Oct; 68(4):821-6. PubMed ID: 6352080
[No Abstract] [Full Text] [Related]
47. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism.
Dale J; Thaulow E; Myhre E; Parry J
Thromb Haemost; 1983 Oct; 50(3):703-6. PubMed ID: 6689091
[TBL] [Abstract][Full Text] [Related]
48. Prevention of acute cyclosporine A nephrotoxicity by a thromboxane synthetase inhibitor.
Smeesters C; Chaland P; Giroux L; Moutquin JM; Etienne P; Douglas F; Corman J; St-Louis G; Daloze P
Transplant Proc; 1988 Jun; 20(3 Suppl 3):658-64. PubMed ID: 3164534
[No Abstract] [Full Text] [Related]
49. Effect of selective inhibition of thromboxane synthesis on renal function in diabetic nephropathy.
Kontessis PS; Jones SL; Barrow SE; Stratton PD; Alessandrini P; De Cosmo S; Ritter JM; Viberti GC
J Lab Clin Med; 1993 Mar; 121(3):415-23. PubMed ID: 8445289
[TBL] [Abstract][Full Text] [Related]
50. Thromboxane-mediated activation of platelets and enhancement of platelet uptake onto collagen-coated glass or deendothelialized rabbit aorta. Comparative effects of a thromboxane antagonist (EPO45) and a thromboxane synthetase inhibitor (dazoxiben).
Menys VC; Davies JA
Lab Invest; 1984 Feb; 50(2):184-9. PubMed ID: 6546403
[TBL] [Abstract][Full Text] [Related]
51. [Effect of hypoxemia and pulmonary thromboembolism on plasma levels of 6-keto PGF 1 alpha, TxB, histamine and serotonin in anesthetized dogs (author's transl)].
Ishihara Y; Kitamura S; Kosaka K; Harasawa M
Nihon Kyobu Shikkan Gakkai Zasshi; 1981 Aug; 19(8):542-8. PubMed ID: 6895531
[No Abstract] [Full Text] [Related]
52. Prostacyclin and thromboxane release from human peritoneal macrophages.
Foegh M; Maddox YT; Winchester J; Rakowski T; Schreiner G; Ramwell PW
Adv Prostaglandin Thromboxane Leukot Res; 1983; 12():45-9. PubMed ID: 6221630
[No Abstract] [Full Text] [Related]
53. Raised plasma levels of thromboxane B2 in systemic mastocytosis.
Ouwendijk RJ; Zijlstra FJ; Wilson JH; Bonta IL; Vincent JE; Stolz E
Eur J Clin Invest; 1983 Jun; 13(3):227-9. PubMed ID: 6409646
[TBL] [Abstract][Full Text] [Related]
54. Increased thromboxane B2 levels in the plasma of burned and septic burned patients.
Herndon DN; Abston S; Stein MD
Surg Gynecol Obstet; 1984 Sep; 159(3):210-3. PubMed ID: 6433494
[TBL] [Abstract][Full Text] [Related]
55. Thromboxane and prostacyclin production during septic shock.
Butler RR; Wise WC; Halushka PV; Cook JA
Adv Shock Res; 1982; 7():133-45. PubMed ID: 6753528
[TBL] [Abstract][Full Text] [Related]
56. Prevention of endotoxin-induced pulmonary hypertension in primates by the use of a selective thromboxane synthetase inhibitor, OKY 1581.
Casey LC; Fletcher JR; Zmudka MI; Ramwell PW
J Pharmacol Exp Ther; 1982 Aug; 222(2):441-6. PubMed ID: 6896528
[TBL] [Abstract][Full Text] [Related]
57. Radioimmunoassay of thromboxane B2 and its preliminary applications.
Wang Z; Hu YH; Zhu GQ; Huang RS; An Y; Cheng JX; Liu JS
Proc Chin Acad Med Sci Peking Union Med Coll; 1988; 3(1):50-4. PubMed ID: 3174616
[No Abstract] [Full Text] [Related]
58. The improvement in endotoxin-induced redistribution of organ blood flow by inhibition of thromboxane and prostaglandin synthesis.
Tempel GE; Cook JA; Wise WC; Halushka PV
Adv Shock Res; 1982; 7():209-18. PubMed ID: 6753535
[No Abstract] [Full Text] [Related]
59. Maternal thromboxane, prostacyclin, and umbilical blood flow in humans.
Ylikorkala O; Jouppila P; Kirkinen P; Viinikka L
Obstet Gynecol; 1984 May; 63(5):677-80. PubMed ID: 6546976
[TBL] [Abstract][Full Text] [Related]
60. Is immunoreactive 6-keto-PGF1 alpha measured in serum after treatment with thromboxane-synthetase inhibitors an index of prostacyclin synthesis?
Cerletti C; Chiabrando C; Fanelli R; de Gaetano G
Lancet; 1984 Apr; 1(8383):967-8. PubMed ID: 6143907
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
